港股沪昊中天医药-B(02563)股价今日盘中大涨9.42%,报28.25港元,引发市场关注。分析人士认为,华昊中天的核心产品优替德隆注射液前景看好,以及公司在港股上市时采取的"套路回拨"和"惜售"的定价策略是导致当日股价大涨的主要原因。
华昊中天是一家合成生物学技术驱动的生物医药公司,专注肿瘤创新药研发。其核心产品优替德隆注射液于2021年获国家药监局批准上市,2022年被纳入国家医保目录。尽管谈判后价格有所下降,但得益于纳入医保后放量,近年来销量有所增长。
此外,华昊中天在香港上市时采取了一些特殊的定价策略。由于国内投资者认购不足,公司仅对港股通投资者"惜售"12%的股份。同时,公司的招股价定在发行区间的下限,与上限价相差37%。这种"惜售"和低价发行的组合策略,使得上市后股价大涨成为大概率事件,从而造就了今天的涨停行情。但华昊中天能否借助业绩持续支撑高估值仍有待观察。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.